Century Therapeutics (IPSC) Research & Development (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Research & Development data on file, last reported at $17.1 million in Q1 2026.

• On a quarterly basis, Research & Development fell 35.65% year-over-year to $17.1 million in Q1 2026; TTM through Mar 2026 was $63.7 million, a 42.33% decrease from a year earlier, with the FY2025 full-year figure at $95.7 million, down 10.8% from the prior year.
• Research & Development for Q1 2026 stood at $17.1 million, down from $19.7 million in the prior quarter.
• Over the last five years, Research & Development for IPSC reached as high as $29.4 million in Q4 2024 and fell as low as $12000.0 in Q3 2025.
• Historically, Research & Development has averaged $22.8 million across 5 years, with a median of $24.5 million in 2022.
• Across the five-year window, Research & Development jumped 37.87% in 2022 and plunged 99.96% in 2025, its largest moves.
• Year by year, Research & Development stood at $25.6 million in 2022, then declined by 12.86% to $22.3 million in 2023, then jumped by 31.75% to $29.4 million in 2024, then slumped by 32.95% to $19.7 million in 2025, then slipped by 13.15% to $17.1 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $17.1 million in Q1 2026, $19.7 million in Q4 2025, and $12000.0 in Q3 2025.